Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
14.39
+0.37 (2.64%)
Feb 21, 2025, 4:00 PM EST - Market closed
Zymeworks Employees
As of December 31, 2023, Zymeworks had 278 total employees, including 272 full-time and 6 part-time employees. The number of employees decreased by 16 or -5.44% compared to the previous year.
Employees
278
Change (1Y)
-16
Growth (1Y)
-5.44%
Revenue / Employee
$223,737
Profits / Employee
-$408,888
Market Cap
991.15M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ZYME News
- 4 days ago - Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors - GlobeNewsWire
- 9 days ago - Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 - GlobeNewsWire
- 23 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - 3 Biotech Stocks With Notable Insider Buying - Seeking Alpha
- 6 weeks ago - Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 - GlobeNewsWire
- 2 months ago - Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule - Seeking Alpha
- 3 months ago - FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - GlobeNewsWire
- 3 months ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - GlobeNewsWire